Business Description
GeNeuro SA
ISIN : CH0308403085
Compare
Compare
Traded in other countries / regions
GNRO.FranceGEM.GermanyGNROp.UKGNRRF.USA IPO Date
2017-03-06Description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | -2.17 | |||||
Debt-to-Equity | -0.97 | |||||
Debt-to-EBITDA | -0.95 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -9.8 | |||||
3-Year EPS without NRI Growth Rate | -11.4 | |||||
3-Year FCF Growth Rate | -4.3 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.37 | |||||
Quick Ratio | 0.37 | |||||
Cash Ratio | 0.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.7 | |||||
Shareholder Yield % | -142.25 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -147.07 | |||||
ROIC % | -234.95 | |||||
ROC (Joel Greenblatt) % | -1262.8 | |||||
ROCE % | -271.32 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.15 | |||||
EV-to-EBITDA | -1.18 | |||||
EV-to-FCF | -1.63 | |||||
Earnings Yield (Greenblatt) % | -86.96 | |||||
FCF Yield % | -202.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with GREY:GNRRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GeNeuro SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | 0 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 0 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 4.55 - 4.55 | ||
Shares Outstanding (Mil) | 24.84 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
GeNeuro SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
GeNeuro SA Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
GeNeuro SA Frequently Asked Questions
What is GeNeuro SA(GNRRF)'s stock price today?
The current price of GNRRF is $4.55. The 52 week high of GNRRF is $4.55 and 52 week low is $4.55.
When is next earnings date of GeNeuro SA(GNRRF)?
The next earnings date of GeNeuro SA(GNRRF) is .
Does GeNeuro SA(GNRRF) pay dividends? If so, how much?
GeNeuro SA(GNRRF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |